ENSYSCE BIOSCIENCES, INC. Net Fee Amt
ENSYSCE BIOSCIENCES, INC. (ENSC) had Net Fee Amt of $53.45 as of 2026-06-04, per its S-3 filed 2026-06-04.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-06-04
- 2026-06-04: Net Fee Amt $53.45.
- 2026-04-30: Net Fee Amt $43.61.
- 2026-04-08: Net Fee Amt $1.47K.
| Period end | Net Fee Amt |
|---|---|
| 2026-06-04 | $53.45 S-3 · filed 2026-06-04 |
| 2026-04-30 | $43.61 S-8 · filed 2026-04-30 |
| 2026-04-08 | $1.47K S-3 · filed 2026-04-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |